U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07683806) titled 'Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis' on June 22.
Brief Summary: This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE(R)) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.
Study Start Date: Aug. 24
Study Type: INTERVENTIONAL
Condition:
Seborrheic Dermatitis
Intervention:
DRUG: Roflumilast Foam 0.3%
Roflumilast foam 0.3% is applied once daily for 8 weeks.
DRUG: Vehicle foam
Vehicle foam is applied once daily for 8 weeks.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hangzhou Zhongmei Huadong Ph...